Active Ingredient History

NOW
  • Now
Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba. It is administered via subcutaneous injection once daily to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 42 hours, making it a once-daily basal insulin, that is one that provides a base insulin level, as opposed to the fast- and short-acting bolus insulins.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$25.1880 - $177.0467
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

|
( liraglutide (victoza), insulin degludec (tresiba) - other name: insulin degludec and liraglutide )
(1a-21a),(1b-29b)-insulin (human), 29b-(n6-(n-(15-carboxy-1- oxopentadecyl)-l-gamma- glutamyl)-l-lysine)- | degludec | ins tresiba | insulin aspart / insulin degludec | insulin degludec | insulin degludec / liraglutide | nn1250 | tresiba

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue